Abstract
: Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.
| Original language | English |
|---|---|
| Pages (from-to) | N/A-N/A |
| Journal | Skin Health and Disease |
| Volume | 4 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2024 |
All Science Journal Classification (ASJC) codes
- Dermatology
Keywords
- psoriasis
Fingerprint
Dive into the research topics of 'Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver